What’s going on with Fibrocell Science’s (FCSC) shares?

According to Zacks Investment Research, the online research company, shares of the Exton based cell therapy developer rose 14% in heavier than normal trading during Friday’s Wall Street trading session.

According to Zacks:

“The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend for the company, as the stock is now trading above the volatile price range of $2.76 to $3.15 in the past one-month timeframe.”

Whose bullish on Fibrocell Sciences and why?

It’s too early to know Why?  Answering the Who? question however, is easier: VC’s, the CEO and the company’s board of directors.

According to the Wall Street Journal, four individuals including CEO David Pernock and three members of the company’s board of directors including Christine St.Clare, Marc Mazur and Kevin Moore joined Third Security LLC, buying 432,057 Fibrocell’s shares Friday.

Friday’s $1.1 million dollar investment by Third Security marked the second time the Radford, Virginia VC firm had staked out a position in Fibrocell, having purchased just over one million shares of the company in January 2014.

More on the story on Zacks here.

Previous coverage of Fibrocell Sciences on Chesco Business Today here, and here.